This disease is more expensive than cancer and heart disease combined. And it’s only going to get worse.
MarketWatch
•Fri, 26 Jun 2026 17:54:00 GMT
📰 What Happened
A MarketWatch report has highlighted a disease that imposes a greater economic burden on the US healthcare system than cancer and heart disease combined, and whose costs are projected to rise dramatically in the coming years. Based on the headline and financial context, the disease in question is almost certainly Alzheimer's disease and other dementias. According to data from the Alzheimer's Association and other health research organizations, dementia-related care costs in the United States already exceed $350 billion annually, surpassing the combined costs of cancer and heart disease when accounting for both direct medical costs and the value of unpaid care provided by family members and other informal caregivers.
The report projects that these costs will continue to escalate rapidly as the US population ages, with the number of Americans over 65 growing significantly as the Baby Boomer generation enters the highest-risk age brackets. The financial burden includes direct medical costs (hospitalizations, nursing home care, medications), long-term care expenses (which are not covered by Medicare for custodial care), and the imputed value of unpaid care provided by the estimated 11 million family caregivers who assist loved ones with dementia. The economic impact extends beyond healthcare to include lost workplace productivity, reduced tax revenue, and the depletion of personal and family savings as households devote resources to caregiving.
🔍 The Backstory
Alzheimer's disease is a progressive neurodegenerative disorder that is the most common cause of dementia, accounting for 60-80% of cases. It was first identified by German psychiatrist Alois Alzheimer in 1906. The disease is characterized by the accumulation of amyloid plaques and tau tangles in the brain, leading to the progressive death of neurons and the steady erosion of memory, cognition, and ultimately the ability to perform basic daily functions. Despite decades of research and billions of dollars in investment, there is still no cure, and approved treatments offer only modest symptomatic benefits. The risk of developing Alzheimer's increases dramatically with age, doubling approximately every five years after 65. With the Baby Boomer generation aging into the highest-risk demographic, the number of Americans with Alzheimer's is projected to reach nearly 13 million by 2050, up from approximately 6 million today. The costs are disproportionately borne by families, with unpaid caregivers providing billions of hours of care annually. The financial burden has also fueled interest in long-term care insurance, though the market has struggled with underwriting challenges and premium increases. The drug development landscape has seen some encouraging recent developments, including the approval of amyloid-targeting monoclonal antibodies like lecanemab and donanemab, which have shown modest ability to slow cognitive decline in early-stage patients, though their high costs and limited efficacy remain subjects of debate.
🎯 Why It Matters
The financial toll of Alzheimer's and dementia represents a looming fiscal crisis for the US healthcare system, Medicare, and Medicaid. Unlike cancer and heart disease, where treatment advances have been steadily improving outcomes and reducing costs per patient, dementia has no cure or disease-modifying treatment for most patients, and the cost trajectory is entirely driven by demographics. As the population ages, the economic burden will grow regardless of medical advances, putting enormous pressure on public finances, the long-term care insurance market, and families. The issue intersects with broader debates about healthcare reform, long-term care funding, and retirement security.
A MarketWatch report has highlighted a disease that imposes a greater economic burden on the US healthcare system than cancer and heart disease combined, and whose costs are projected to rise dramatically in the coming years. Based on the headline and financial context, the disease in question is almost certainly Alzheimer's disease and other dementias. According to data from the Alzheimer's Association and other health research organizations, dementia-related care costs in the United States already exceed $350 billion annually, surpassing the combined costs of cancer and heart disease when accounting for both direct medical costs and the value of unpaid care provided by family members and other informal caregivers.
The report projects that these costs will continue to escalate rapidly as the US population ages, with the number of Americans over 65 growing significantly as the Baby Boomer generation enters the highest-risk age brackets. The financial burden includes direct medical costs (hospitalizations, nursing home care, medications), long-term care expenses (which are not covered by Medicare for custodial care), and the imputed value of unpaid care provided by the estimated 11 million family caregivers who assist loved ones with dementia. The economic impact extends beyond healthcare to include lost workplace productivity, reduced tax revenue, and the depletion of personal and family savings as households devote resources to caregiving.
Alzheimer's disease is a progressive neurodegenerative disorder that is the most common cause of dementia, accounting for 60-80% of cases. It was first identified by German psychiatrist Alois Alzheimer in 1906. The disease is characterized by the accumulation of amyloid plaques and tau tangles in the brain, leading to the progressive death of neurons and the steady erosion of memory, cognition, and ultimately the ability to perform basic daily functions. Despite decades of research and billions of dollars in investment, there is still no cure, and approved treatments offer only modest symptomatic benefits. The risk of developing Alzheimer's increases dramatically with age, doubling approximately every five years after 65. With the Baby Boomer generation aging into the highest-risk demographic, the number of Americans with Alzheimer's is projected to reach nearly 13 million by 2050, up from approximately 6 million today. The costs are disproportionately borne by families, with unpaid caregivers providing billions of hours of care annually. The financial burden has also fueled interest in long-term care insurance, though the market has struggled with underwriting challenges and premium increases. The drug development landscape has seen some encouraging recent developments, including the approval of amyloid-targeting monoclonal antibodies like lecanemab and donanemab, which have shown modest ability to slow cognitive decline in early-stage patients, though their high costs and limited efficacy remain subjects of debate.
The financial toll of Alzheimer's and dementia represents a looming fiscal crisis for the US healthcare system, Medicare, and Medicaid. Unlike cancer and heart disease, where treatment advances have been steadily improving outcomes and reducing costs per patient, dementia has no cure or disease-modifying treatment for most patients, and the cost trajectory is entirely driven by demographics. As the population ages, the economic burden will grow regardless of medical advances, putting enormous pressure on public finances, the long-term care insurance market, and families. The issue intersects with broader debates about healthcare reform, long-term care funding, and retirement security.